SMPL, PBI and MMS made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 9, 2026.

The heavy selling pressure might have exhausted for Maximus (MMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

AAUC, BBVA, MMS, SIMO and MS have been added to the Zacks Rank #1 (Strong Buy) List on February 9, 2026.

MMS beats Q1 fiscal 2026 earnings estimates, but a revenue miss and softer full-year sales outlook kept the quarter mixed.

Maximus, Inc. (MMS) Q1 2026 Earnings Call Transcript

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

The headline numbers for Maximus (MMS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Maximus (MMS) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.61 per share a year ago.

TYSONS, Va.--(BUSINESS WIRE)--Maximus reports financial results for the three months ending December 31, 2025.

Van Berkom and Associates Inc. lessened its stake in Maximus, Inc. (NYSE: MMS) by 8.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,161,125 shares of the health services provider's stock after selling 104,474 shares during the quarter. Maximus comprises about 3.1%